

Alder BioPharmaceuticals appoints Dr Paul Streck as CMO

21 January 2019 | News

Dr Streck will report to Bob Azelby, Alder's president and chief executive officer



Alder BioPharmaceuticals, a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine has announced the appointment of Paul Streck, M.D., as chief medical officer (CMO), effective January 21, 2019.

He will report to Bob Azelby, Alder's president and chief executive officer.

Dr. Streck brings more than 25 years of experience in drug development, regulatory and medical affairs leadership across both large and small publicly traded biopharmaceutical companies. He joins Alder from Insmed Incorporated, where he served as chief medical officer and played an instrumental role as a member of the executive leadership team, successfully leading the Arikayce regulatory filing, approval and launch.

Prior to Insmed, Dr. Streck was GlaxoSmithKline (GSK) plc's group vice president and global medical lead of the Immunoinflammation division responsible for the immunology portfolio strategy, including Benlysta and sirukumab.

Before GSK, Dr. Streck spent eight years at Shire plc, culminating in his role as group vice president, clinical development for hematology, gastrointestinal and internal medicine. In this role, Dr. Streck led a team of 50 people and was responsible for thirteen clinical trial programs and regulatory filings across various product lifecycle stages. Prior to Shire plc, Dr. Streck held a variety of medical affairs and commercial roles over five years with Amgen Inc.

Dr. Streck succeeds Alder's interim CMO, Eric Carter who has been responsible for leading the preparation of the Biologics License Application (BLA) for eptinezumab and ensuring its submission in the first quarter of 2019. Dr. Carter will continue to work closely with the company as a consultant following the transition.

Bob Azelby said, "Paul brings extensive experience with regulatory interactions, clinical trial execution, and product lifecycle management, as well as leading medical affairs organizations, and we are delighted to welcome him to the Alder team. This experience, coupled with his deep operating expertise, will be highly valuable as we continue to engage with the U.S. Food and Drug Administration (FDA), including through our planned BLA submission for eptinezumab later this quarter, and to build out our medical and commercial infrastructure in anticipation of the potential launch in the first quarter of 2020."

"I'm excited to join Alder's strong leadership team and have been inspired by the company's commitment to transform the treatment paradigm for millions of patients debilitated by migraine. This is an important time for Alder and for migraine patients. I look forward to working with the Alder team to ensure the successful approval and launch of eptinezumab and the growth of Alder as a leader in novel migraine therapeutics", said Dr. Streck.

Streck received his medical degree from Jefferson Medical College. He also holds a doctor of dental medicine degree from Temple University's School of Dentistry, and a master's of business administration from Fuqua School of Business at Duke University.